TAK
Takeda’s psoriasis pitch got louder
Takeda dropped topline Phase 3 data for zasocitinib (TAK-279), and the headline is about as subtle as a marching band: it beat Bristol-Myers Squibb’s Sotyktu in a head-to-head study of adults with moderate-to-severe plaque psoriasis.
The good stuff
In the LATITUDE Atlas trial, Takeda says zasocitinib hit statistical superiority on the main endpoint, PASI 100 response at week 16. That means more patients got completely clear skin — the kind of result that makes dermatologists lean in and investors start thinking in blockbuster-sized numbers.
The drug also apparently outperformed Sotyktu on the key secondary endpoints too, including:
- PASI 90 response
- sPGA 0 at week 16
And because biotech news without a safety note would feel illegal, Takeda says the drug was generally well tolerated, with no new safety signals popping up.
Why Wall Street cares
This isn’t just about bragging rights in a psoriasis cage match. Takeda has said before that, if approved, zasocitinib could bring in $3 billion to $6 billion in peak annual sales. So every clean win like this makes the eventual launch story look a little less like “maybe” and a little more like “oh, that could actually matter.”
What happens next
Takeda said it plans to present detailed data at upcoming medical congresses and is still on track to file for U.S. and other regulatory approvals starting this fiscal year. Translation: the story is moving from “promising data” to “show me the filing paperwork.”
Big picture: Takeda just turned a clinical trial into a louder commercial argument. If the data hold up, TAK-279 could become one of those drugs that quietly sneaks into the big leagues.